White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy

por Dahl, Edgar, Villwock, Sophia, Habenberger, Peter, Choidas, Axel, Rose, Michael, Klebl, Bert M.
Publicado 2022

Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia

por Johansson, Patricia, Dierichs, Laura, Klein-Hitpass, Ludger, Bergmann, Anke K., Möllmann, Michael, Menninger, Sascha, Habenberger, Peter, Klebl, Bert, Siveke, Jens T., Dührsen, Ulrich, Choidas, Axel, Dürig, Jan
Publicado 2020

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia

por Johansson, Patricia, Klein-Hitpass, Ludger, Choidas, Axel, Habenberger, Peter, Mahboubi, Bijan, Kim, Baek, Bergmann, Anke, Scholtysik, René, Brauser, Martina, Lollies, Anna, Siebert, Reiner, Zenz, Thorsten, Dührsen, Ulrich, Küppers, Ralf, Dürig, Jan
Publicado 2018

Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form

por Aarhus, Thomas Ihle, Bjørnstad, Frithjof, Wolowczyk, Camilla, Larsen, Kristin Uhlving, Rognstad, Line, Leithaug, Trygve, Unger, Anke, Habenberger, Peter, Wolf, Alexander, Bjørkøy, Geir, Pridans, Clare, Eickhoff, Jan, Klebl, Bert, Hoff, Bård H., Sundby, Eirik
Publicado 2023

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

por Brägelmann, Johannes, Dammert, Marcel A., Dietlein, Felix, Heuckmann, Johannes M., Choidas, Axel, Böhm, Stefanie, Richters, André, Basu, Debjit, Tischler, Verena, Lorenz, Carina, Habenberger, Peter, Fang, Zhizhou, Ortiz-Cuaran, Sandra, Leenders, Frauke, Eickhoff, Jan, Koch, Uwe, Getlik, Matthäus, Termathe, Martin, Sallouh, Muhammad, Greff, Zoltán, Varga, Zoltán, Balke-Want, Hyatt, French, Christopher A., Peifer, Martin, Reinhardt, H. Christian, Örfi, László, Kéri, György, Ansén, Sascha, Heukamp, Lukas C., Büttner, Reinhard, Rauh, Daniel, Klebl, Bert M., Thomas, Roman K., Sos, Martin L.
Publicado 2017